Northwestern Medicine scientists have created and transplanted an artificial ovarian system that induced puberty in mouse models, a first step toward a new approach to improving fertility in childhood cancer survivors.
Northwestern Medicine scientists used “big data” tools to classify for the first time three distinct categories of a common heart failure syndrome. The findings may be used to better predict how diverse patients will respond to treatments.
Xunrong Luo, MD, PhD, associate professor in Medicine-Nephrology, Microbiology-Immunology and Surgery-Organ Transplantation, has been selected to receive the American Society of Transplantation Basic Science Investigator Award.
Chad Mirkin, PhD, and colleagues show that spherical nucleic acids can be used to regulate immune responses in a new study that could shift the way scientists think about developing therapeutic agents for many diseases.
Northwestern Medicine scientists have identified mechanisms behind desmosomes, important junctions that bind cells together, helping to explain how some skin and heart diseases develop.
A Northwestern Medicine study found that standard treatments for metastatic melanoma are not effective against Nodal, a growth factor protein critical for the skin cancer’s development, but also showed that combination therapies incorporating anti-Nodal antibodies are a promising alternative.
Feinberg is one of the nation’s top 20 medical schools in the annual U.S. News & World Report rankings, with women’s health, internal medicine and pediatrics positioned highly in medical specialty rankings.
Northwestern Medicine scientists have developed a method to systematically explore diverse natural resources, allowing them to quickly identify thousands of compounds from bacteria that have potential to become new pharmaceuticals.
A Northwestern Medicine study has identified new genetic mutations in patients with Wilms tumor, the most common kidney tumor in children.
In a recent review published in Nature Reviews Cardiology, Northwestern Medicine investigators outline strategies to reduce the rate of early postdischarge adverse events among patients with heart failure.